Last fall, the Executive Committee of the Society responded to grave concern over the impact that across-the-board cuts to the National Institutes of Health (NIH) budget would have on critical research by establishing the ASH Bridge Grant Program. The Bridge Grant is a key priority of the organization and demonstrates the Society’s commitment to protecting the careers of those who are dedicated to hematology research.
This year and for the next two years, the Bridge Grant Program will provide at least 30 one-year awards annually, in the amount of $100,000 each, to ASH members who applied for an NIH R01 grant or equivalent, but their proposals went unfunded because of budget cutbacks. The long-term goal of the award is to help sustain research in the field and to contribute to retention of outstanding investigators focused on hematology research.
The first round of award winners was announced in mid-April. The 17 investigators who will be receiving the $1.7 million in grant money are from various U.S. institutions and represent a wide spectrum of seniority – four are professors, seven are associate professors, and six are assistant professors. Nine of the 17 funded projects focus on non-malignant diseases. Research supported by ASH’s inaugural round of bridge grants spans the breadth of hematology. Funded projects range from characterizing a gene signaling pathway that will provide a better understanding of the basis of chemotherapy resistance in children with acute myeloid leukemia to exploring how red blood cells respond to oxidative stress. Other projects that received ASH bridge grant funding include a study designed to gain insight into gene signaling in lymphoma, a project aimed at characterizing a critical marker of blood-forming stem cells, and a study of how proteins, when modified, induce arterial thrombosis. View the list of award recipients.
Beyond the Society’s financial commitment through 2015, additional awards will be supported by corporate and individual donors. Generous support from Amgen, Atlanta Convention & Visitors Bureau, Genentech, GlaxoSmithKline, Millennium: The Takeda Oncology Company, and Novartis enabled the Society to award additional Bridge Grants in the first round.
Applications for the second round of funding were due in mid-April, and the recipients will be announced in July.
Details About the Award
- From 2013 through 2015, ASH will award at least 90 (30 per year) $100,000 bridge grants, for a total investment of $9 million.
- ASH membership is required at the time of application to the Bridge Grant Program and must be maintained throughout the award period.
- There will be two award cycles per year.
The Society is currently seeking support from individual and corporate donors in order to provide additional awards. Make a donation to this program.